IPHA
Innate Pharma S.A.NASDAQHealthcare$1.37+1.48%ClosedMarket Cap: $128.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-4.89
P/S
39.09
EV/EBITDA
-1.76
DCF Value
$-0.08
FCF Yield
-48.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-2161.0%
Net Margin
-1764.5%
ROE
593.9%
ROA
-78.4%
ROIC
-163.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.1M | 0.0% | $-32.4M | $-27.6M | $-0.28 | — |
| FY 2025 | $2.7M | 0.0% | $-57.9M | $-47.2M | $-0.53 | — |
| Q2 2025 | $4.9M | -322.2% | $-25.4M | $-21.3M | $-0.25 | — |
| Q4 2024 | $276.0K | 10634.8% | $-25.3M | $-24.7M | $-0.30 | — |
| FY 2024 | $12.6M | 100.0% | $-51.6M | $-49.5M | $-0.61 | — |
| Q2 2024 | $12.3M | -135.5% | $-26.3M | $-24.8M | $-0.31 | — |
| Q4 2023 | $16.6M | -18.9% | $-7.4M | $-9.3M | $-0.12 | — |
| FY 2023 | $51.9M | 10.8% | $-12.7M | $-7.6M | $-0.09 | — |
| Q2 2023 | $35.3M | 55.5% | $-5.3M | $1.7M | $0.02 | — |
| Q4 2022 | $8.3M | -60.7% | $-28.8M | $-64.4M | $-0.80 | — |
| FY 2022 | $57.7M | 10.4% | $-57.4M | $-58.1M | $-0.73 | — |
| Q2 2022 | $41.3M | 69.8% | $4.2M | $6.3M | $0.08 | — |